{"id":"W4288950951","doi":"10.1016/j.ejca.2022.03.016","title":"EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Chugai Pharmaceutical; Genentech; Geistlich Pharma; PharmaMar; Ono Pharmaceutical; Eisai; NuCana; EMD Serono; Mersana Therapeutics; Deciphera Pharmaceuticals; Clovis Oncology; Incyte; Taiho Pharmaceutical; Regeneron Pharmaceuticals; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Quality of life (healthcare); Medicine; Cervical cancer; Internal medicine; Population; Chemotherapy; Oncology; Cancer; Physical therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005890898,0.0002720083,0.0008683371,0.0002124826,0.0001509465,0.0003367552,0.0002570123,0.0004253626,0.003717962],"category_scores_gemma":[0.001317684,0.0001294906,0.0008811581,0.0002112294,0.0002192469,0.0003982968,0.0003317094,0.0008098925,0.0001982719],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004075142,"about_ca_system_score_gemma":0.0005872516,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001398682,"about_ca_topic_score_gemma":0.003831444,"domain_scores_codex":[0.9997229,0.0001189387,0.00001945967,0.00004123196,0.00002817417,0.00006937614],"domain_scores_gemma":[0.9996125,0.0001432172,0.00009662019,0.00002131401,0.00001628532,0.0001100005],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6800249,0.01642417,0.06891306,0.001206255,0.002791457,0.0000950007,0.0004280886,0.0020694,0.007303408,0.0002243897,0.001858519,0.2186614],"study_design_scores_gemma":[0.09484208,0.5091267,0.3795939,0.0002507698,0.004227814,0.0001896476,0.0006376686,0.002575322,0.004274064,0.0003740363,0.003827537,0.00008042607],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9977419,0.001163508,0.00001983835,0.0001140518,0.0000261794,0.00004452511,0.0003137521,0.000008912719,0.0005673688],"genre_scores_gemma":[0.9984176,0.0003938685,0.00009755245,0.0001079867,0.00003147346,0.00008870755,0.0003105362,0.000002068394,0.0005501995],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003717962,"threshold_uncertainty_score":0.01243782,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0221888486003094,"score_gpt":0.2960530835257411,"score_spread":0.2738642349254317,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}